Global Expansion

With its cultivation and manufacturing base domiciled in Australia, LGP is seeking to capitalise on Australia’s international reputation for high quality, trusted products born from its leading agricultural and production practices. 

UK
LGP has identified the UK as a highly prospective territory with the industry forecast to grow to £$1.05 billion (A$2.10 billion) by 2024, with an expected 400,000 patients being prescribed medicinal cannabis (reference: 3 Prohibition Partners, The UK Cannabis Report, p 14 - 46).

In April 2020, Little Green Pharma announced the first export of Australian medicinal cannabis products for patients to the UK. The products were distributed in the UK by Astral Health, a UK-based specialist importer and distributor of medicinal cannabis products and a subsidiary of the LYPHE Group.

Australia’s Minister for Health, the Honourable Greg Hunt said: “This first export of Australian-produced medicinal cannabis oils to the UK marks an important step in fulfilling Australia’s vision of building a global medicinal cannabis industry capable of supplying quality medicinal cannabis products to both Australian and overseas patients.”

 

Germany

LGP has now delivered its first commercial shipment of 2,400 units of LGP GMP-manufactured medicinal cannabis oils to CC Pharma GmbH in Germany. This makes LGP the third global medicinal cannabis manufacturer to deliver full plant extract oils into Germany, the third largest medicinal cannabis market globally and the largest medicinal cannabis market currently available to Australian producers. Due to limited local German production, Germany’s primary source of medicinal cannabis is through imports from overseas suppliers, with the market estimated to grow to €1.5 billion by 2025.

The Company remains well placed to service the German market: in addition to its CC Pharma distributorship, the Company has also entered into a three year agreement with Demecan for the sale and export of up to 1,000 kg of dried flower or 48,000 units of medicinal cannabis oil per annum. The Company anticipates making its first commercial delivery to Demecan in the first quarter of CY2021.